Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label pilot study of induction therapy with a single high dose bolus of intravenous methotrexate with leucovorin rescue, prior to initiation of AVONEX [interferon-beta-1a] treatment, in patients presenting with a first acute demyelinating event: comparison with CHAMPS results

Next Previous
Search
Trial Profile

An open label pilot study of induction therapy with a single high dose bolus of intravenous methotrexate with leucovorin rescue, prior to initiation of AVONEX [interferon-beta-1a] treatment, in patients presenting with a first acute demyelinating event: comparison with CHAMPS results

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 17 Apr 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon beta-1a (Primary) ; Methotrexate; Methylprednisolone
  • Indications Multiple sclerosis
  • Focus Therapeutic Use

Most Recent Events

  • 03 Feb 2010 Additional lead trial centre identified as reported by ClinicalTrials.gov.
  • 17 Dec 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
  • 06 Oct 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top